Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
STCUF$0.34-0.02(-5.18%)Star Copper Expands Historical Copper System with Largest Drill Program in Project History with Pervasive Mineralization Across Multiple Intercepts[3:01:00 AM ET]UNFYF$0.20-0.00(-0.40%)Edge Total Intelligence to Attend TechNet Indo-Pacific 2026[3:01:00 AM ET]EDVMF$51.61-0.98(-1.86%)Transaction in Own Shares[3:00:00 AM ET]CTHCF$0.88+0.01(+0.64%)Mkango Magnetic Materials Limited Announces HyProMag USA Pre-Feasibility Study[3:00:00 AM ET]EQNR$48.10-0.72(-1.47%)Equinor ASA: Share buy-back – third tranche for 2026[3:00:00 AM ET]EPMLF$0.420.00(0.00%)Empire Metals Limited Announces Pilot-Scale Testing and Scoping Study Update[3:00:00 AM ET]ONWRY$2.640.00(0.00%)ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026[2:30:00 AM ET]

PHAR · NASDAQ

Pharming Group N.V.

$11.84 +0.65 (+5.76%)

Company overview

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of Pompe and Fabry diseases.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$750M
Employees
404
Headquarters
Leiden
Website
pharming.com
CEO
Fabrice Chouraqui
Listed
December 23, 2020
P/E
64.00
Dividend yield
0.00%

Company financials

Revenue
$369M
Gross profit
$322M
Operating income
$23.4M
EBITDA
$39.5M
Net income
$12.3M
EPS
$0.19
Total assets
$489M
Total debt
$116M
Gross margin
87.28%
Net margin
3.34%
Earnings yield
1.56%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

8.7910.9313.0615.1917.33
PHAR 1D NASDAQ O11.65H11.90L11.57C11.85+0.65 (+5.76%)Vol6.92K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PHARPharming Group N.V. Press release Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November GlobeNewswire
PHARPharming Group N.V. Stock news Pharming Group (PHAR) Expected to Release Quarterly Earnings on Tuesday Defense World
PHARPharming Group N.V. Press release Pharming Group announces third quarter 2026 revenues above market expectations GlobeNewswire
PHARPharming Group N.V. Press release Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 GlobeNewswire
PHARPharming Group N.V. Stock news Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes Seeking Alpha
PHARPharming Group N.V. Press release Pharming announces CEO transition GlobeNewswire
PHARPharming Group N.V. Press release Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS GlobeNewsWire
PHARPharming Group N.V. Press release Pharming announces positive Phase II topline data for GlobeNewswire
PHARPharming Group N.V. Stock news MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR Defense World
PHARPharming Group N.V. Press release FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S. GlobeNewsWire
PHARPharming Group N.V. Press release Pharming Group to participate in September investor conferences GlobeNewswire
PHARPharming Group N.V. Legal Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky PRNewsWire
PHARPharming Group N.V. Stock news Ratio makes improved bid for Pharos Energy Proactive Investors
PHARPharming Group N.V. Legal Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Business Wire
PHARPharming Group N.V. Legal Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR) GlobeNewsWire
PHARPharming Group N.V. Stock news Analysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33 Defense World
PHARPharming Group N.V. Press release Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS Globe News Wire
PHARPharming Group N.V. Stock news Pharming Group Q1 Earnings Call Highlights MarketBeat
PHARPharming Group N.V. Stock news Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript Seeking Alpha
PHARPharming Group N.V. Press release Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders GlobeNewsWire
See more
FAQ

Questions about Pharming Group N.V.

What does Pharming Group N.V. do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of Pompe and Fabry diseases.
What is PHAR's market cap?
Pharming Group N.V. (PHAR) is a listed stock with a live quote. The latest market cap on this page is $750M.
Where is Pharming Group N.V. headquartered?
Pharming Group N.V. is headquartered in Leiden.
How do I get PHAR news from the API?
Call GET /v1/news?tickers=PHAR. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does PHAR news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PHAR, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the PHAR price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs